Longbio-b

Status: Publicly traded

Direct answer

Longbio-b is publicly traded on HKSE under the ticker 1779.HK.

Longbio Pharma (Suzhou) Co., Ltd. operates as a clinical-stage biotechnology company. It focuses on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. The company was founded by Heng Liu and Nai-Chau Sun on October 26, 2020 and is headquartered Suzhou, China.

Can you invest in Longbio-b?

Yes. Longbio-b trades publicly on HKSE as 1779.HK.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Longbio-b

Detailed equity research is provided by MarketSnap.